

Sanofi (SNY)

\$45.15 (As of 04/15/20)

Price Target (6-12 Months): **\$52.00**

Long Term: 6-12 Months

Zacks Recommendation:

Outperform

(Since: 04/14/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5)

1-Strong Buy

Zacks Style Scores:

VGM:A

Value: A


Growth: C

Momentum: C

Summary

Sanofi's Specialty Care segment is on a strong footing, particularly with regular label expansion of Dupixent. The performance of the Vaccines franchise has also improved of late. Sanofi's R&D pipeline is strong and it delivered several positive data readouts and achieved regulatory milestones in 2019 with the momentum expected to continue in 2020. Its cost savings and efficiency initiatives are supporting bottom-line growth. However, headwinds include weak performance of the Diabetes unit, generic competition for many drugs and slower-than-expected uptake of core products like Praluent. Shares have outperformed the industry in the past year. Estimates have gone down slightly, ahead of Q1 earnings release due to the expected impact of coronavirus on earnings. Sanofi has a positive record of earnings surprise in the recent quarters.


Price, Consensus & Surprise



Data Overview

| | |
|----------------------------|---|
| 52 Week High-Low | \$51.84 - \$37.62 |
| 20 Day Average Volume (sh) | 3,449,188 |
| Market Cap | \$113.1 B |
| YTD Price Change | -10.1% |
| Beta | 0.57 |
| Dividend / Div Yld | \$1.21 / 2.6% |
| Industry | Large Cap Pharmaceuticals |
| Zacks Industry Rank | Top 7% (17 out of 253) |

Sales and EPS Growth Rates (Y/Y %)



| | |
|---------------------------|------------|
| Last EPS Surprise | 5.7% |
| Last Sales Surprise | -4.4% |
| EPS F1 Est- 4 week change | -0.0% |
| Expected Report Date | 04/24/2020 |
| Earnings ESP | 0.0% |
| P/E TTM | 13.4 |
| P/E F1 | 13.0 |
| PEG F1 | 1.9 |
| P/S TTM | 2.8 |

Sales Estimates (millions of \$)

| | Q1 | Q2 | Q3 | Q4 | Annual* |
|------|---------|----------|----------|----------|----------|
| 2021 | | | | | 44,574 E |
| 2020 | 9,849 E | 10,168 E | 11,231 E | 11,295 E | 42,736 E |
| 2019 | 9,529 A | 9,696 A | 10,561 A | 10,639 A | 40,002 A |

EPS Estimates

| | Q1 | Q2 | Q3 | Q4 | Annual* |
|------|----------|----------|----------|----------|----------|
| 2021 | | | | | \$3.83 E |
| 2020 | \$0.82 E | \$0.78 E | \$1.03 E | \$0.82 E | \$3.47 E |
| 2019 | \$0.81 A | \$0.74 A | \$1.07 A | \$0.74 A | \$3.32 A |

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 04/15/2020. The reports text is as of 04/16/2020.

Overview

Sanofi, located in Paris, France, manufactures and markets prescription drugs in Europe, the United States and other countries. It focuses on major therapeutic areas such as cardiovascular, immunology, oncology and diabetes, among others. Sanofi operates through three segments Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines via Sanofi Pasteur


In April 2011, Genzyme Corporation became a subsidiary of Sanofi. With this deal, Sanofi has expanded its presence in biotech and now has products like Cerezyme, Myozyme/Lumizyme and Fabrazyme in its portfolio. Sanofi swapped its Merial Animal Health businesses with Boehringer Ingelheim's Consumer Healthcare (CHC) business in January 2017.

Sanofi has collaboration agreements with companies like Regeneron and Alnylam among others. Sanofi has developed and markets Dupixent, Kevzara, Praluent and Libtayo in collaboration with Regeneron.

Sanofi reports through five Global Business Units (GBUs) namely Sanofi Genzyme (Specialty Care – 25.5% of 2019 sales), Primary Care (25%), China & Emerging Markets (20.6%), Consumer Healthcare (13%) and Vaccines (15.9%). The Sanofi Genzyme and Primary Care units do not include Emerging Markets sales, which are included in China & Emerging Markets GBU

At its Capital Markets Day held in December 2019, Sanofi announced plans to restructure the company's operations under three GBUs – Specialty Care (immunology, rare diseases, rare blood disorders, neurology and oncology), Vaccines and General Medicines (diabetes, cardiovascular, and established products). The company's Consumer Healthcare (CHC) will operate as a standalone business unit.

In 2019, total sales declined 2.8% (at CER) to €36.1 billion.



Reasons To Buy:

- ▲ **Shares Outperforming Industry:** Sanofi's share price has risen 10% in the past year, outperforming the industry's increase of 9.8%.
- ▲ **Diversified Product Portfolio and New Product Launches:** Sanofi possesses a diversified product portfolio with a presence in several therapeutic areas including multiple sclerosis, cardiovascular diseases, diabetes, oncology, immunology, among others. Sanofi has also been progressing with new product launches.

Sanofi's Specialty Care segment is on a strong footing, particularly with the regular label expansion of Dupixent. The drug could prove to be key long-term driver.

Sanofi's new immunology drug Dupixent is now annualizing at around €2.7 billion in sales after just around two years on the market. Sanofi expects Dupixent to achieve more than €10 billion in peak sales. Dupixent now is approved in the United States and the EU for three type II inflammatory diseases, namely severe chronic rhinosinusitis with nasal polyposis, severe asthma and moderate-to-severe atopic dermatitis. The frequent label expansion approvals are driving the drug sales higher with the positive trend expected to continue in the future quarters. We are optimistic about the sales prospects of Dupixent, which could prove to be an important catalyst for the company.

Libtayo/cemiplimab was approved in the United States in September 2018 and in the EU in July 2019 for the treatment of cutaneous squamous cell carcinoma. Libtayo is the only treatment approved by the FDA for this potentially life-threatening form of skin cancer. Cablivi (caplacizumab), for the treatment of a rare blood disorder called acquired thrombotic thrombocytopenic purpura, was approved by the FDA in February 2019 and in the EU in September 2018. Sarcisa (isatuximab) was approved in the United States for relapsed/refractory (third-line) multiple myeloma (RRMM) in March 2019.

Sanofi is investing in these launches to optimize their success. In fact, Sanofi's new products are now delivering revenues greater than the LoE impact.

- ▲ **Strong Vaccine Segment:** Sanofi possesses one of the world's leading vaccine operations, with total sales of more than €5 billion in the past three years (2017-2019). The company's portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccine spaces.

Sanofi continues to expand its vaccine business further. Sanofi has also beefed up its Chinese presence with a new vaccine manufacturing facility in Shenzhen. Sanofi expects sales in its Vaccine unit to grow at mid-to-high single digit CAGR from 2018 to 2025.

- ▲ **Robust Pipeline:** Sanofi has shifted its R&D focus on Specialty Care therapy areas (oncology, immunology, rare disease and rare blood disorder) and Vaccines. Its programs in these areas have increased significantly since 2017. At the beginning of February 2020, Sanofi's pipeline included 39 pharmaceutical new molecular entities and vaccine candidates, which were in phase III studies or under regulatory review.

Promising candidates include dupilumab (bullous pemphigoid, chronic spontaneous urticaria, prurigo nodularis, eosinophilic esophagitis and chronic obstructive pulmonary disease — phase III; peanut allergy and grass pollen allergy — phase II), cemiplimab (first line non-small cell lung cancer in combination studies — phase III, metastatic and locally advanced basal cell carcinoma — phase II, second-line treatment of cervical cancer — phase III), fitusiran (hemophilia A and B — phase III), sutimlimab (cold agglutinin disease — phase III), sarilumab (Kevzara) (giant cell arteritis and polymyalgia rheumatica — phase III; systemic juvenile arthritis and polyarticular juvenile idiopathic arthritis — phase II), nirsevimab vaccine (respiratory syncytial virus (RSV) — phase III), fully liquid meningococcal vaccine, MenQuadfi (under review in the United States and the EU), BTK inhibitor/SAR442168 (relapsing multiple sclerosis — phase II) and isatuximab (newly diagnosed multiple myeloma and second line r/r multiple myeloma — phase III).

- ▲ **Acquisitions and Deals to Drive Growth:** Sanofi has also significantly stepped up its acquisition and alliance activity over the past few years. The company diversified into the rare diseases segment with the Genzyme deal which provided the company with a new source of growth. The acquisition boosted Sanofi's revenues as well as its pipeline. Products like Fabrazyme, Aubagio and Cerdelga became part of Sanofi's portfolio through the Genzyme acquisition. Sanofi has also expanded its presence in biotechnology with this acquisition.

With the acquisition of Chattem in 2010, Sanofi has become a major player in the CHC sector. This acquisition has helped Sanofi establish a strong presence in the U.S. CHC market. Moreover, in order to realign its portfolio, the company swapped businesses with Boehringer — Sanofi's Merial (enterprise value of €11.4 billion) was exchanged with Boehringer's CHC business (worth €6.7 billion). The deal allowed Sanofi to strengthen its position in several categories including Pain Care, Allergy Solutions, Cough & Cold Care, Feminine Care, Digestive Health and Vitamins, Minerals and Supplements.

Sanofi has a 21.2% stake in Regeneron (as of Dec 31, 2019) and has also extended its agreement with Alnylam to develop RNAi therapeutics for rare genetic diseases. The company has been actively striking deals related to diabetes and oncology. The 2018 acquisitions of Ablynx and Bioverativ and the in-licensing of fitusiran from Alnylam have strengthened Sanofi's position in the rare blood disorders market.

Sanofi bought small cancer biotech Synthorx in early 2020 which added Synthorx's lead pipeline asset, THOR-707 to Sanofi's immuno-oncology portfolio. THOR-707 is being evaluated across multiple solid tumor types alone and in combination with immune checkpoint inhibitors.

We expect to see more such activities on the acquisition and collaboration front.

- ▲ **Cost Cutting Initiatives:** Sanofi's cost savings come from simplification of its organization, enhanced manufacturing productivity, streamlining of products portfolio and alignment of sales force.

In Dec 2019, Sanofi said that it is discontinuing all its research activities in diabetes and cardiovascular area to help it focus on high growth franchises. Meanwhile, the company said it will prioritize key growth drivers — Dupixent and vaccines and six investigational therapies,

including fitusiran, venglustat & nirsevimab. Along with these restructuring initiatives, Sanofi also announced a cost-saving plan, which is expected to generate €2 billion in savings. Sanofi expects business operating income margin to improve to 30% by 2022.

Risks

- **Sales Decline in Diabetes Franchise:** Sanofi's Diabetes franchise is under significant pressure with key product, Lantus (insulin glargine), facing increasing competitive pressure at the payor level and biosimilar competition in several European markets and Japan. Moreover, a biosimilar insulin glargine hit the U.S. markets in December 2016. Lantus was a major contributor to the company's top line having accounted for 10.3% of total sales in 2017 and 7.3% in 2018.

Sales of Sanofi's global diabetes franchise declined 11% in 2017, 17.5% in 2018 and 15.6% in 2019. Lantus sales declined more than 25% in the past three years (2017-2019) with sales in the United States declining in all years due to lower average net price and loss of Medicare Part D business. In Europe too, Lantus sales declined in all years due to biosimilar competition and patient switching to Toujeo

- **Generics Impacting Revenues:** Sanofi has faced significant loss of revenues in the last couple of years as several of its key products went off patent including its blockbuster drug, Plavix. Meanwhile, sales of drugs like Lantus and Renagel declined in 2018 and 2019 due to loss of exclusivity.
- **Praluent Sales Yet to Pick Up:** While Praluent was launched in 2015, sales have been below expectations since launch due to payer restrictions. Prescription volumes remain subdued in key markets with treatment being reserved only for very severe patients.

Sanofi has been actively negotiating with U.S. payers to simplify the utilization management criteria and improve access to Praluent. Sanofi and Regeneron lowered Praluent's U.S. net price for those payers who agreed to reduce access barriers for high-risk heart patients. Though these efforts have paid off, the improved access came at the cost of significantly higher rebates, which hurt profits from the drug's sales. In February 2019, Sanofi announced a 60% cut in the U.S. list price of Praluent to improve access and affordability of the drug. However, the lower prices as well as the significantly higher rebates significantly dented Sanofi's profits from Praluent in 2019. Sales declined 7.6% in 2019.

Meanwhile, though Sanofi has gained approval to include data from the phase III cardiovascular outcome study on Praluent's label in the United States as well as EU, it remains to be seen if the label expansion leads to improved demand trends.

We note that Amgen's Repatha is also approved both in the U.S. and in the EU. Potential competitors that could enter the market include Anylam/Novartis' Inclisiran (under review in the United States and EU).

Last Earnings Report

Sanofi's Q4 Earnings Top, Sales Miss

Sanofi reported fourth-quarter 2019 earnings of 74 cents per American depositary share, which beat the Zacks Consensus Estimate of 70 cents. Earnings increased 21.8% on a reported basis. At constant currency rates (CER), earnings rose 17.3% driven by higher revenues and lower costs.

Net sales rose 6.8% on a reported basis to \$10.64 billion (€9.6 billion). Exchange rate movements benefited sales by 2.1% driven by a strong dollar and Japanese yen. At CER, sales increased 4.7% year over year. Sales however missed the Zacks Consensus Estimate of \$11.12 billion.

Double-digit growth in Specialty Care and Vaccines was offset by persistent sluggishness in Diabetes and Cardiovascular franchises and a weak performance in the CHC unit in the quarter.

Sales rose 11.8% at CER in the United States and 1.8% in the Emerging Markets. Sales were flat in Europe at CER but rose 0.6% in the Rest of the World (Japan, South Korea, Canada, Australia, New Zealand and Puerto Rico).

All growth rates mentioned below are on a year-on-year basis and at CER.

Segmental Performance

Pharmaceuticals sales (including the emerging markets) rose 2.4% in the fourth quarter to €6.55 billion driven by Dupixent, which was partially offset by lower Diabetes and Established Rx products sales.

Sanofi **Genzyme/Specialty Care GBU** sales (excluding the emerging markets) increased 19.7% to €2.53 billion, driven by Dupixent.

In the immunology franchise, Dupixent generated sales of €668 million in the quarter, up 133.1%. Sales of the drug in the United States were €545 million, up 134.7% driven by continued growth in atopic dermatitis and rapid uptake in new asthma indication and launch in chronic rhinosinusitis with nasal polyposis in June 2019. Sales in Europe were €64 million, up 117.2%.

Kevzara recorded sales of €53 million in the quarter, up 64.5%.

Sales of rare disease drugs increased 0.8% to €661 million against a high base for comparison. Myozyme/Lumizyme rose 2.1% to €197 million, Fabrazyme sales were €186 million, up 0.6%. Cerezyme sales declined 6.3% to €121 million.

Oncology sales increased 12.6% to €333 million. Key cancer drug Jevtana's sales were up 10.1% to €123 million supported by higher sales in the United States.

Sales of multiple sclerosis drugs declined 3.8% to €517 million. Aubagio sales increased 3.9% to €465 million while sales of Lemtrada fell 42.5% to €52 million.

Rare blood disorders franchise, added to Sanofi's portfolio with the acquisition of Bioverativ in 2018, fetched sales of €293 million, down 2.4% year over year. New drug Cablivi (caplacizumab) generated sales of €16 million in the quarter, lower than €20 million in the previous quarter, primarily due to price adjustments in Europe and increased assistance program participation in the United States. Sales of another drug in the franchise, Eloctate declined 14.9% in the quarter due to the ongoing competitive pressure in the United States.

Primary Care GBU comprises the Diabetes and Cardiovascular and the Established Rx Products segments. Sales in the Primary Care GBU declined 8.7% to €2.33 billion hurt by lower sales in Diabetes and Established Products.

The Diabetes franchise (excluding the emerging markets) declined 15.5% to €861 million due to lower sales of key drug Lantus.

Sales of diabetes drugs in the United States declined 20.5% to €454 million due to pricing pressure and loss of Part D business. In Europe, it dropped 4.4% and in rest of the world, it declined 21.8%.

Lantus sales decreased 23.9% to €485 million in the quarter. Lantus sales plunged 26.9% in the United States due to lower average net price and change in coverage with respect to Sanofi's Part D business. In Europe, sales decreased 13.1% due to biosimilar competition and patient switching to Toujeo.

Toujeo generated sales of €186 million in the reported quarter, up 1.7%. Sales rose 14.3% in Europe while it declined 7.4% in the United States.

Admelog, a rapid-acting insulin, similar to Lilly's Humalog, achieved sales worth €56, down 1.8% year over year.

In the cardiovascular franchise, Praluent, garnered worldwide sales of €68 million in the reported quarter, down 14.1%. Sales in the United States declined due to significantly higher rebates offered by Sanofi and partner Regeneron to payers to improve access to the drug. Sales of the other drug, Multaq, in this franchise rose 1.1% to €97 million.

Sales of Established Rx Products came in at €1.3 billion, down 4% mainly due to lower sales of Plavix and Aprovel in China due to anticipated price and inventory adjustments in the channel following the implementation of the VBP program in China in December. Meanwhile, lower sales of Lovenox in Europe and generic competition for Renvela/Renagel in the United States also hurt segment sales.

Sales of **China and Emerging Markets GBU** declined 1.9% to €1.7 billion.

Quarter Ending **12/2019**

| Report Date | Feb 06, 2020 |
|------------------|--------------|
| Sales Surprise | -4.37% |
| EPS Surprise | 5.71% |
| Quarterly EPS | 0.74 |
| Annual EPS (TTM) | 3.36 |

Consumer Healthcare GBU (including the emerging markets) sales were €1.15 billion, down 5.2% as higher sales in Emerging Markets were offset by lower sales in the United States and Europe. Sales declined 12.8% in the United States due to Sanofi's voluntary recall of its over-the-counter acid reflux medicine Zantac.

FDA tests, results of which were released in September, found low levels of a chemical called NDMA, which has been classified as a probable human carcinogen in multiple ranitidine products. This prompted Sanofi and a couple of companies marketing the generic ranitidine to recall their products.

Meanwhile, non-core divestments and increased regulatory requirements, which resulted in product suspensions, also hurt the performance of the CHC segment. These factors are expected to dent sales in the first half of 2020 as well.

Moreover, in Europe, sales decreased 11.7% to €325 million, reflecting divestments of non-strategic brands and strengthening regulatory requirements.

Sanofi Pasteur (Vaccines) GBU sales (including the emerging markets) rose 22% to €1.91 billion. U.S. sales of vaccines rose 33.1% in the quarter, reflecting the majority of U.S. influenza vaccine shipments in the fourth quarter. Sales also rose in Emerging Markets and Europe.

Costs Decline

Selling, general and administrative expenses declined 1.4% at CER in the quarter, reflecting cost-control measures. Research and development expenses declined 0.7% at CER due to smart spending initiatives as well as portfolio prioritization.

2020 Guidance

Sanofi expects earnings to grow approximately 5% at CER in 2020. It anticipates a positive currency impact of around 1% on earnings. In 2020, while strong growth from Dupixent and vaccines should pull up sales, the impact from VBP in China and the Zantac recall will hurt the top-line mostly in the first half. The company expects earnings growth to be weighted toward the second half. Also, the first quarter of 2020 will face difficult comparisons from the year-ago quarter as a result of strong 22% sales growth reported in China in the first quarter of 2019.

Recent News

Collaborates With Glaxo to Make Adjuvanted COVID-19 Vaccine – Apr 14

Sanofi and Glaxo signed a letter of intent to combine their innovative technologies to develop an adjuvanted COVID-19 vaccine. The vaccine candidate is expected to enter clinical studies in the second half of 2020. The vaccine, if successfully developed, will be available in the second half of 2021.

To make the vaccine, Sanofi will contribute the S-protein COVID-19 antigen developed using its recombinant DNA technology, which has helped produce an exact genetic match to proteins found on the surface of the virus.

Meanwhile, Glaxo will provide its proven pandemic adjuvant technology for the development of the coronavirus vaccine candidate. This technology may reduce the amount of vaccine protein required per dose, which, in turn, will allow more vaccine doses to be produced.

Proven technologies of these leading companies may lead to a better and scalable coronavirus vaccine, which is the need of the hour

To Donate Hydroxychloroquine– Apr 10

Sanofi announced that it will donate 100 million doses of hydroxychloroquine, which it markets by the name of Plaquenil across 50 countries. Sanofi has increased its production capacity by 50% and is on track to further increase production over the coming months. Meanwhile, clinical studies are evaluating hydroxychloroquine for the treatment of COVID-19.

Praluent Restructuring Finalized – Apr 6

Sanofi announced that it has finalized the planned restructuring related to Praluent. From Apr 1, it will have sole responsibility for Praluent outside the United States while Regeneron will have sole responsibility for Praluent in the country.

Dupixent Data Positive in Atopic Dermatitis – Apr 3

Regeneron and Sanofi announced detailed positive results from a phase III study evaluating Dupixent in children aged 6-11 years with uncontrolled severe atopic dermatitis. The data showed that the drug when combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related quality of life in these children. At 16 weeks, approximately three times as many children who were treated with Dupixent and TCS achieved clear or almost clear skin. More than two-thirds experienced at least a 75% overall improvement compared to TCS alone. In addition, more than three times as many children experienced a significant reduction in itch with Dupixent and TCS compared to TCS alone.

A supplemental BLA for the drug in this indication is currently under Priority Review with a target action date of May 26, 2020.

Initiates Outside U.S. Study on Kevzara for Severe Coronavirus Infection – Mar 30

Sanofi announced the initiation of a phase II/III study outside the United States to evaluate IL-6 inhibitor, Kevzara to treat patients hospitalized with severe infection due to COVID-19. The study has been initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients. The first patient in the study has been treated. In March, Regeneron/Sanofi announced plans to study Kevzara for severe COVID-19 infection. Regeneron initiated a U.S. based phase II/III study last month. While Regeneron is leading the U.S. studies, Sanofi is taking care of the ex-U.S. studies.

CHMP Nod for Sarclisa – Mar 27

Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of its anti-CD38 monoclonal antibody, Sarclisa (isatuximab). The opinion is for approving Sarclisa in combination with standard-of-care medicines, pomalidomide and dexamethasone (pom-dex) for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

To Make Coronavirus Vaccine with Translate Bio – Mar 27

Sanofi announced a collaboration with Translate Bio to jointly develop a novel messenger RNA (mRNA) vaccine for COVID-19. Both companies already have a collaboration and exclusive licensing agreement to develop mRNA vaccines for up to five infectious disease pathogens, which was signed in 2018.

The companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development. Translate Bio has begun to produce multiple mRNA constructs and will use its mRNA platform to discover, design and manufacture SARS-CoV-2 vaccine candidates. Meanwhile, Sanofi will provide deep vaccine expertise and support from its external research networks to advance vaccine candidates for potential further development.

To Evaluate Kevzara for Severe Coronavirus Infection – Mar 18

Regeneron and Sanofi announced the initiation of a U.S. based phase II/III study to evaluate Kevzara, to treat patients hospitalized with severe infection due to COVID-19. While Regeneron will lead U.S. studies, Sanofi will take care of the ex-U.S. studies. Kevzara is an anti-interleukin (IL)-6 receptor monoclonal antibody and the companies believe that in critically-ill COVID-19 patients, the IL-6 pathway may play an important role in driving overactive inflammatory response in lungs and emerge as a treatment option.

Valuation

Sanofi's shares have declined 10% in the year-to-date period but are up 10% over the trailing 12-month period. Stocks in the Zacks sub-industry and sector are down 4.2% and 7.6%, respectively, in the year-to-date period. Over the past year, stocks in the sub-industry and sector are up 9.8% and 0.3%, respectively.

The S&P 500 Index is down 11.8% in the year-to-date period and 2.4% in the past year.

The stock is currently trading at 12.62X forward 12-month earnings per share, which compares with 14.34X for the Zacks sub-industry, 20.5X for the Zacks sector and 18.99X for the S&P 500 index.

Over the past five years, the stock has traded as high as 16.9X and as low as 10.89X, with a 5-year median of 13.34X. Our Outperform recommendation indicates that the stock will perform better than the market. Our \$52 price target reflects 14.5X forward 12-month earnings per share.

The table below shows summary valuation data for SNY

| Valuation Multiples - SNY | | | | | |
|---------------------------|---------------|-------|--------------|--------|---------|
| | | Stock | Sub-Industry | Sector | S&P 500 |
| P/E F12M | Current | 12.62 | 14.34 | 20.5 | 18.99 |
| | 5-Year High | 16.9 | 18.12 | 21.07 | 19.34 |
| | 5-Year Low | 10.89 | 13.04 | 15.81 | 15.19 |
| | 5-Year Median | 13.34 | 15.38 | 18.81 | 17.45 |
| P/S F12M | Current | 2.61 | 4.49 | 2.61 | 3.16 |
| | 5-Year High | 3.34 | 4.83 | 3.84 | 3.44 |
| | 5-Year Low | 2.16 | 3.92 | 2.25 | 2.54 |
| | 5-Year Median | 2.59 | 4.39 | 2.96 | 3.01 |
| P/B TTM | Current | 1.71 | 5.13 | 3.57 | 3.77 |
| | 5-Year High | 2.25 | 7.19 | 5.04 | 4.54 |
| | 5-Year Low | 1.45 | 3.8 | 3.01 | 2.9 |
| | 5-Year Median | 1.7 | 5.2 | 4.29 | 3.64 |

As of 4/15/2020

Industry Analysis Zacks Industry Rank: Top 7% (17 out of 253)



Top Peers

| | |
|----------------------------------|------------|
| Eli Lilly and Company (LLY) | Outperform |
| AbbVie Inc. (ABBV) | Neutral |
| Bayer Aktiengesellschaft (BAYRY) | Neutral |
| GlaxoSmithKline plc (GSK) | Neutral |
| Merck & Co., Inc. (MRK) | Neutral |
| Novartis AG (NVS) | Neutral |
| Pfizer Inc. (PFE) | Neutral |
| Roche Holding AG (RHHBY) | Neutral |

| Industry Comparison Industry: Large Cap Pharmaceuticals | | | | Industry Peers | | |
|---|----------------|------------|-----------|----------------|-------------|-------------|
| | SNY Outperform | X Industry | S&P 500 | BAYRY Neutral | GSK Neutral | MRK Neutral |
| VGM Score | A | - | - | A | B | B |
| Market Cap | 113.06 B | 134.23 B | 19.18 B | 57.78 B | 99.36 B | 208.15 B |
| # of Analysts | 5 | 3 | 14 | 2 | 6 | 7 |
| Dividend Yield | 2.56% | 2.57% | 2.24% | 3.52% | 5.62% | 2.97% |
| Value Score | A | - | - | A | B | B |
| Cash/Price | 0.09 | 0.06 | 0.06 | 0.11 | 0.07 | 0.05 |
| EV/EBITDA | 10.51 | 12.49 | 11.46 | 8.15 | 10.16 | 14.58 |
| PEG Ratio | 1.94 | 1.87 | 2.08 | 1.11 | 7.49 | 2.13 |
| Price/Book (P/B) | 1.71 | 3.99 | 2.58 | 1.09 | 4.24 | 8.04 |
| Price/Cash Flow (P/CF) | 6.80 | 10.97 | 10.15 | 4.45 | 9.19 | 12.27 |
| P/E (F1) | 13.01 | 14.47 | 17.24 | 8.05 | 13.51 | 14.47 |
| Price/Sales (P/S) | 2.80 | 4.29 | 1.99 | 1.14 | 2.31 | 4.44 |
| Earnings Yield | 7.69% | 6.91% | 5.64% | 12.40% | 7.41% | 6.91% |
| Debt/Equity | 0.36 | 0.57 | 0.70 | 0.78 | 1.29 | 0.87 |
| Cash Flow (\$/share) | 6.64 | 4.33 | 7.01 | 3.48 | 4.33 | 6.69 |
| Growth Score | C | - | - | C | C | B |
| Hist. EPS Growth (3-5 yrs) | 0.74% | 8.34% | 10.92% | NA | 6.31% | 8.10% |
| Proj. EPS Growth (F1/F0) | 4.52% | 8.17% | -2.92% | 8.76% | -7.04% | 9.25% |
| Curr. Cash Flow Growth | 26.95% | 4.27% | 5.93% | -8.03% | 4.83% | 5.54% |
| Hist. Cash Flow Growth (3-5 yrs) | 5.29% | 7.62% | 8.55% | 6.30% | 1.08% | 0.15% |
| Current Ratio | 1.40 | 1.26 | 1.24 | 1.40 | 0.81 | 1.24 |
| Debt/Capital | 26.32% | 39.95% | 42.36% | 43.72% | 56.24% | 46.65% |
| Net Margin | 7.78% | 22.35% | 11.64% | 9.07% | 13.72% | 21.01% |
| Return on Equity | 25.84% | 32.05% | 16.74% | 13.85% | 57.93% | 49.41% |
| Sales/Assets | 0.65 | 0.49 | 0.54 | 0.35 | 0.47 | 0.56 |
| Proj. Sales Growth (F1/F0) | 5.72% | 5.64% | 0.00% | -3.06% | 4.54% | 4.13% |
| Momentum Score | C | - | - | A | A | D |
| Daily Price Chg | -1.78% | -0.97% | -3.26% | -4.56% | -1.39% | -0.93% |
| 1 Week Price Chg | 1.41% | 5.20% | 16.01% | 9.83% | 4.68% | 8.18% |
| 4 Week Price Chg | 8.40% | 14.21% | 16.73% | 15.77% | 16.16% | 14.57% |
| 12 Week Price Chg | -8.60% | -8.60% | -22.44% | -25.35% | -16.68% | -8.46% |
| 52 Week Price Chg | 9.88% | 9.88% | -14.41% | -10.46% | -0.40% | 11.02% |
| 20 Day Average Volume | 3,449,188 | 4,928,015 | 3,301,889 | 1,024,426 | 5,134,523 | 13,162,771 |
| (F1) EPS Est 1 week change | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -0.55% |
| (F1) EPS Est 4 week change | -0.05% | -0.77% | -6.78% | -0.77% | -0.45% | -0.90% |
| (F1) EPS Est 12 week change | -0.26% | -0.10% | -9.07% | -4.47% | -5.86% | 2.48% |
| (Q1) EPS Est Mthly Chg | 0.00% | -2.59% | -11.31% | NA | 0.00% | -7.26% |

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

| | |
|----------------|----------|
| Value Score | A |
| Growth Score | C |
| Momentum Score | C |
| VGM Score | A |

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.